secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001140361-24-036294
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M
-----------------------------------------------------------------------

- Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.
- Net loss of $4.68M ($0.21 per share) compared to $2.89M ($0.22 per share) a year ago.
- Cash and cash equivalents $13.5M; expects to fund operations into July 2025.
- Received CE Mark for four women's health products; completed U.S. commercial team build-out.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/0001140361-24-036294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/ef20033802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-036294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer